Faruqi & Faruqi Investigates Claims Against Tvardi Therapeutics
Faruqi & Faruqi, LLP, a well-respected national securities law firm, is currently looking into possible claims on behalf of investors in Tvardi Therapeutics, Inc. (NASDAQ: TVRD). This investigation has arisen from recent events surrounding the company's stock performance.
Significant Stock Price Drop
Recently, Tvardi Therapeutics experienced a staggering decline in its stock value, dropping more than 80%. This sharp decrease followed disappointing preliminary results from the Phase 2 REVERT clinical trial for its TTI-101 treatment in patients with idiopathic pulmonary fibrosis. The aim of the study was to evaluate the safety and potential effectiveness of the drug.
Details of the Clinical Trial
The Phase 2 REVERT trial was carefully designed to assess various aspects of the treatment, including safety, pharmacokinetics, and exploratory outcomes related to lung function. Following an in-depth analysis of the preliminary data, which included important metrics such as changes in Forced Vital Capacity (FVC), the overall conclusion was that the trial did not meet its predefined goals. This revelation has raised concerns among investors regarding the viability of the treatment.
Legal Rights for Affected Investors
For investors who have faced considerable financial losses due to their investments in Tvardi, there are options available to discuss legal recourse and potential claims. It's crucial for stakeholders feeling the impact of these developments to seek advice from professionals who can guide them through the necessary steps.
Contacting Faruqi & Faruqi
Josh Wilson, a partner at Faruqi & Faruqi, is inviting impacted investors to reach out for a discussion of their legal rights and options. Interested parties can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for personalized assistance regarding their circumstances.
About Faruqi & Faruqi
The firm has been a leader in the securities law field since its establishment in 1995, successfully recovering substantial amounts for investors over the years. Their dedicated team is based out of several locations, including New York, Pennsylvania, California, and Georgia. With a history of advocating for investor rights, they are committed to providing expert guidance during turbulent times.
Staying Updated
For those wanting to keep abreast of further developments concerning Tvardi Therapeutics, it’s advisable to follow official updates from Faruqi & Faruqi. The firm actively provides information on their website and through various social media channels, including LinkedIn, X, and Facebook.
Frequently Asked Questions
What is the reason for the investigation by Faruqi & Faruqi?
The firm is investigating potential claims from investors who have suffered losses due to the significant drop in Tvardi's stock price, linked to disappointing clinical trial results.
How can investors contact Faruqi & Faruqi?
Investors can directly reach out to Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for assistance with their legal rights.
What were the trial results that led to stock decline?
The Phase 2 clinical trial for TTI-101 did not meet its safety and efficacy goals, leading to concerns about the drug's market viability.
Where is Faruqi & Faruqi located?
The firm has offices in New York, Pennsylvania, California, and Georgia.
What kind of support does Faruqi & Faruqi provide to investors?
Faruqi & Faruqi provides legal guidance and support to investors looking to understand their options in light of financial losses.
